LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00567619
First received: September 20, 2007
Last updated: February 14, 2008
Last verified: February 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency & severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists
- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca
| Condition |
|---|
|
GERD |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS) |
Further study details as provided by AstraZeneca:
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with newly occured upper GI symptoms related to GERD
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00567619 History of Changes |
| Other Study ID Numbers: | NIS-GAT-NEX-2007/1 |
| Study First Received: | September 20, 2007 |
| Last Updated: | February 14, 2008 |
| Health Authority: | Not required for this study: |
Keywords provided by AstraZeneca:
|
GERD NIS |
Additional relevant MeSH terms:
|
Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders |
Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013